09 September 2021
Aleksandr Tkachenko, Chairman of the Board of the Circle of Kindness Foundation, said that it is very important that Russia develops its own drugs for the treatment of children with severe chronic diseases, including rare ones.
At BIOCAD, Tkachenko was told about the preparation of clinical trials of ANB-4, a domestically developed drug for gene therapy of spinal muscular atrophy (SMA). Its mechanism of action makes it possible to get a significant result after a single dose, as in the case of the Swiss drug Zolgensma.
According to the head of the Circle of Kindness, today the Foundation has provided the necessary treatment for 1,345 children for the total amount of about 25 billion rubles.
“I think it is crucial that Russian manufacturers that have excellent research potential and sufficient production capacity offer their solutions for the treatment of severe and rare diseases. If Russian pharmaceutical manufacturers direct their efforts to develop medicines for seriously ill children, I am confident that this will ensure consistent treatment of children regardless of the decisions of foreign suppliers; even more children will be provided with high-quality medicines. Now both the country’s security in the field of national health and the lives of thousands of children depend on the success of our pharmaceutical industry,” Alexander Tkachenko said.
Earlier, it became known that the Circle of Kindness Foundation now has an information hotline.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024